|
|
Vaccine Detail
|
Survivin/p53/HER2 Antigen-loaded Autologous Dendritic Cell Vaccine |
| Vaccine Information |
- Vaccine Name: Survivin/p53/HER2 Antigen-loaded Autologous Dendritic Cell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007043
- Type: Dendritic cell vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: ERBB2, Survivin, Trp53
- Survivin
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- ERBB2
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- TP53
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: This is for Breast Cancer and Melanoma Cancer (NCT00978913). An autologous dendritic cell (DC) vaccine loaded with tumor-associated antigens (TAAs) derived from survivin, p53 and human epidermal growth factor receptor 2 (HER2 or ERBB2), with immunostimulating and antineoplastic activities. Upon administration, this DC vaccine may elicit a potent cytotoxic T-cell (CTL) response against tumor cells expressing these TAAs, resulting in tumor cell death. Survivin, p53 and HER2 are essential in neoplastic growth, and are considered to be universal tumor antigens (Lo et al., 2005; NCIT_C114285).
|
| Host Response |
|
|
| References |
Lo et al., 2005: Lo HW, Day CP, Hung MC. Cancer-specific gene therapy. Advances in genetics. 2005; 54; 235-255. [PubMed: 16096014].
NCIT_C114285: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C114285]
NCT00978913: [https://clinicaltrials.gov/ct2/show/NCT00978913]
|
|
